Impact of Cassia Bark Consumption on Glucose and Lipid Control in Type 2 Diabetes: An Updated Systematic Review and Meta-Analysis.

Impact of Cassia Bark Consumption on Glucose and Lipid Control in Type 2 Diabetes: An Updated Systematic Review and Meta-Analysis.
复制标题

DOI:
10.7759/cureus.16376
复制
发表时间:
2021-07
期刊:
Cureus
影响因子:
--
通讯作者:
Mirza A
Mirza A
中科院分区:
其他
文献类型:
--
作者:
Mandal A;Sharma S;Rani R;Ranjan S;Kant R;Mirza A

文献摘要

被引文献

相似文献

控制糖尿病是一项持续的挑战,人们正在与现代医学一起寻找自然疗法。肉桂的治疗效果尚未达成共识。除此之外,早期的试验在使用的产品类型、数量、持续时间、分子形式等方面存在差异。因此,我们的目的是测量桂皮粉的消耗量(每天 1-2 克,持续 90 天)对降低 2 型糖尿病患者的血糖和血脂的影响。作者使用肉桂、肉桂、中国肉桂和 2 型糖尿病的 MeSH 术语和关键词检索了 PubMed、Medline、Embase、CINAHL、Clinical Key、Ovid 和 Scopus 数据库以及 Cochrane 中央注册库(上次检索时间为 2020 年 12 月 30 日),根据至少报告了一项的人体临床试验证据,得出了肉桂对糖尿病的影响。以下各项:糖化血红蛋白 (HbA1C)、空腹血糖、总胆固醇、甘油三酯、低密度脂蛋白 (LDL) 和高密度脂蛋白 (HDL)。使用 RevMan 软件(The Cochrane Collaboration,伦敦,英国)的随机效应模型计算加权平均差异,汇总分析发现结果变量的减少不显着(p>0.05)。
Control of diabetes is a constant challenge and natural remedies are being searched along with modern medicine. The effectiveness of cinnamon in managing it lacks consensus. Besides this, earlier trials had a variant in the type of product they used, quantity, duration, the form of molecules, etc. So, we aimed to measure the impact of cassia ground bark powder consumption, 1-2 gm/day for 90 days, in lowering plasma glucose and lipids among those with type 2 diabetes. The authors searched the PubMed, Medline, Embase, CINAHL, Clinical Key, Ovid, and Scopus databases and the Cochrane Central Register (last search December 30, 2020) with the MeSH terms and keywords of cinnamon, cassia cinnamon, Chinese cinnamon, and type 2 diabetes mellitus to conclude the effects of cassia cinnamon on diabetes based on the evidence of human clinical trials that reported at least one of the following: glycosylated hemoglobin (HbA1C), fasting blood glucose, total cholesterol, triglycerides, low-density lipoprotein (LDL), and high-density lipoprotein (HDL). Weighted mean differences were calculated by using the random-effect model of RevMan software (The Cochrane Collaboration, London, UK), and the pooled analysis found an insignificant reduction of the outcome variable (p>0.05).